ulbi20170802_8k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 
 

FORM 8-K

 
 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 
 

August 3, 2017

(Date of Report)

 
 

ULTRALIFE CORPORATION

(Exact name of registrant as specified in its charter)

 
 

Delaware

000-20852

16-1387013

(State of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 

2000 Technology Parkway, Newark, New York

14513

(Address of principal executive offices)

(Zip Code)

 

(315) 332-7100

(Registrant’s telephone number, including area code)

 
 
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging growth company   [ ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [ ]

 

 

 

 
 

 

 

Item 2.02           Results of Operations and Financial Condition

 

NEWARK, N.Y. – August 3, 2017 -- Ultralife Corporation (NASDAQ: ULBI) reported operating income of $1.3 million on revenue of $19.9 million for the second quarter ended July 2, 2017. For the second quarter of 2016, the Company reported operating income of $0.5 million on revenue of $20.4 million.

 

“Building on our solid first quarter performance, for the second quarter on a year-over-year basis we more than doubled operating income and doubled EPS to $0.07. We are also encouraged that our year-over-year core product revenues increased 15% when excluding last year’s VIPER shipments. Battery & Energy Products produced an 11% increase in commercial sales, including 10% higher medical sales, while Communications Systems delivered a 92% increase in core product sales. These strong sales gains demonstrate effective execution of our diversification strategy and the benefit of investments we have made in new product development and sales reach expansion. In line with this strategy, we have made a strategic decision to invest up to $4.3 million of capital in our Newark facility for the manufacture of primary batteries for the high-growth, wireless internet of things device market,” said Michael D. Popielec. “Looking ahead, we are seeing initial indications of increased demand from government/defense customers and are well positioned to continue growing our commercial sales. As a result, we believe we remain on track to deliver another year of profitable growth.”

 

Revenue was $19.9 million, a decrease of $.4 million, or 2%, compared to $20.4 million for the second quarter of 2016 reflecting a $1.1 million increase in Battery & Energy Products sales offset by $1.5 million lower Communications Systems sales. Battery & Energy Products sales increased 7% to $16.9 million compared to $15.8 million last year, reflecting increases in both commercial and government/defense sales of 11% and 1%, respectively. The gain in commercial sales included 10% growth of medical batteries and chargers. Communications Systems sales declined 34% to $3.1 million compared to $4.6 million for the same period last year which included $3.0 million of Vehicle Installed Power Enhanced Riflemen Appliqué (“VIPER”) shipments, while sales of core products such as our 20-watt amplifiers, universal vehicle adaptors and power supplies increased 92% over the prior-year period.

 

Gross profit was $6.2 million, or 31.2% of revenue, compared to $5.9 million, or 29.0% of revenue, for the same quarter a year ago. Battery & Energy Products’ gross margin was 28.1%, compared to 29.6% last year, a decrease of 150 basis points due primarily to incremental supply chain and logistics fees incurred this quarter. Communications Systems’ gross margin increased to 48.4%, the highest level ever reported for the segment, compared to 26.8% for the prior year demonstrating the high value proposition associated with our core amplifier and integrated solutions products.

 

Operating expenses were $4.9 million compared to $5.4 million last year, a reduction of 9.3% reflecting continued tight control over discretionary spending in line with our business model. Operating expenses were 24.6% of revenue compared to 26.5% of revenue for the year earlier period.

 

Operating income was $1.3 million compared to $0.5 million last year.

 

Net income was $1.1 million, or $0.07 per share, compared to net income of $0.4 million, or $0.03 per share, for the second quarter of 2016. Earnings per share for the trailing twelve-month period increased to $.36 compared to $.32 at the end of the first quarter of 2017.

 

The information set forth in this Form 8-K and the attached exhibit is being furnished to and not filed with the Securities and Exchange Commission and shall not be deemed as incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, except to the extent specifically provided in any such filing.

 

 
 

 

 

Item 9.01     Financial Statements, Pro Forma Financials and Exhibits

 

(a) Exhibits.

  

Exhibit      
Number   Description  
       

99.1

 

Press Release of Ultralife Corporation dated August 3, 2017.

 

 

 
 

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: August 3, 2017

 

ULTRALIFE Corporation

     
     
 

By:

/s/ Philip A. Fain

   

Philip A. Fain

   

Chief Financial Officer and Treasurer

 

 
 

 

 

EXHIBIT INDEX

 

Exhibit      
Number   Description  
       

99.1

 

Press Release of Ultralife Corporation dated August 3, 2017.

 

 

 

 

 

ex99-1.htm

Exhibit 99.1

 

Company Contact:  

Investor Relations Contact:

Ultralife Corporation 

LHA

Philip A. Fain 

Jody Burfening

(315) 210-6110 

(212) 838-3777

pfain@ulbi.com   

jburfening@lhai.com

 

                                 

 

Ultralife Corporation Reports Second Quarter Results

 

NEWARK, N.Y. – August 3, 2017 -- Ultralife Corporation (NASDAQ: ULBI) reported operating income of $1.3 million on revenue of $19.9 million for the second quarter ended July 2, 2017. For the second quarter of 2016, the Company reported operating income of $0.5 million on revenue of $20.4 million.

 

“Building on our solid first quarter performance, for the second quarter on a year-over-year basis we more than doubled operating income and doubled EPS to $0.07. We are also encouraged that our year-over-year core product revenues increased 15% when excluding last year’s VIPER shipments. Battery & Energy Products produced an 11% increase in commercial sales, including 10% higher medical sales, while Communications Systems delivered a 92% increase in core product sales. These strong sales gains demonstrate effective execution of our diversification strategy and the benefit of investments we have made in new product development and sales reach expansion. In line with this strategy, we have made a strategic decision to invest up to $4.3 million of capital in our Newark facility for the manufacture of primary batteries for the high-growth, wireless internet of things device market,” said Michael D. Popielec. “Looking ahead, we are seeing initial indications of increased demand from government/defense customers and are well positioned to continue growing our commercial sales. As a result, we believe we remain on track to deliver another year of profitable growth.”

 

 

Second Quarter 2017 Financial Results

 

Revenue was $19.9 million, a decrease of $.4 million, or 2%, compared to $20.4 million for the second quarter of 2016 reflecting a $1.1 million increase in Battery & Energy Products sales offset by $1.5 million lower Communications Systems sales. Battery & Energy Products sales increased 7% to $16.9 million compared to $15.8 million last year, reflecting increases in both commercial and government/defense sales of 11% and 1%, respectively. The gain in commercial sales included 10% growth of medical batteries and chargers. Communications Systems sales declined 34% to $3.1 million compared to $4.6 million for the same period last year which included $3.0 million of Vehicle Installed Power Enhanced Riflemen Appliqué (“VIPER”) shipments, while sales of core products such as our 20-watt amplifiers, universal vehicle adaptors and power supplies increased 92% over the prior-year period.

 

Gross profit was $6.2 million, or 31.2% of revenue, compared to $5.9 million, or 29.0% of revenue, for the same quarter a year ago. Battery & Energy Products’ gross margin was 28.1%, compared to 29.6% last year, a decrease of 150 basis points due primarily to incremental supply chain and logistics fees incurred this quarter. Communications Systems’ gross margin increased to 48.4%, the highest level ever reported for the segment, compared to 26.8% for the prior year demonstrating the high value proposition associated with our core amplifier and integrated solutions products.

 

 
 

 

 

Operating expenses were $4.9 million compared to $5.4 million last year, a reduction of 9.3% reflecting continued tight control over discretionary spending in line with our business model. Operating expenses were 24.6% of revenue compared to 26.5% of revenue for the year earlier period.

 

Operating income was $1.3 million compared to $0.5 million last year.

 

Net income was $1.1 million, or $0.07 per share, compared to net income of $0.4 million, or $0.03 per share, for the second quarter of 2016. Earnings per share for the trailing twelve-month period increased to $.36 compared to $.32 at the end of the first quarter of 2017.

 

 

About Ultralife Corporation

 

Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government, defense and commercial customers across the globe.

 

Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorporation.com.

 

 

Conference Call Information

 

Ultralife will hold its second quarter earnings conference call today at 10:00 AM ET. To participate in the live call, please dial (800) 915-4836 at least ten minutes before the scheduled start time, identify yourself and ask for the Ultralife call. A live webcast of the conference call will be available to investors in the Events & Presentations section of the Company's website at http://investor.ultralifecorporation.com. For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.

 

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include: potential reductions in revenues from key customers, uncertain global economic conditions and acceptance of our new products on a global basis. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife’s financial results is included in Ultralife’s Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.

 

 
 

 

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

 

CONSOLIDATED BALANCE SHEETS

(Dollars in Thousands)

 

(Unaudited)

 
                 
   

ASSETS

 
             
   

July 2,

   

December 31,

 
   

2017

   

2016

 

Current Assets:

               

Cash and Cash Equivalents

  $ 15,016     $ 10,706  

Trade Accounts Receivable, Net

    13,543       13,179  

Inventories

    24,490       23,456  

Prepaid Expenses and Other Current Assets

    1,754       2,079  

Total Current Assets

    54,803       49,420  
                 

Property, Equipment and Improvements, Net

    7,833       7,999  

Goodwill, Intangibles and Other Assets

    27,629       27,325  

Total Assets

  $ 90,265     $ 84,744  
                 
   

LIABILITIES AND SHAREHOLDERS' EQUITY

 
   

Current Liabilities:

               

Accounts Payable

  $ 7,647     $ 7,292  

Accrued Compensation and Related Benefits

    1,875       1,258  

Accrued Expenses and Other Current Liabilities

    2,352       2,778  

Total Current Liabilities

    11,874       11,328  

Deferred Income Taxes and Other Non-Current Liabilities

    5,642       5,556  

Total Liabilities

    17,516       16,884  
                 

Shareholders' Equity:

               

Common Stock

    1,957       1,932  

Capital in Excess of Par Value

    179,519       178,163  

Accumulated Deficit

    (87,793 )     (90,542 )

Accumulated Other Comprehensive Loss

    (2,327 )     (3,080 )

Treasury Stock

    (18,443 )     (18,443 )

Total Ultralife Equity

    72,913       68,030  

Non-Controlling Interest

    (164 )     (170 )

Total Shareholders’ Equity

    72,749       67,860  
                 

Total Liabilities and Shareholders' Equity

  $ 90,265     $ 84,744  

 

 
 

 

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(In Thousands Except Per Share Amounts)

(Unaudited)

 

 

   

Three Month Periods Ended

   

Six Month Periods Ended

 
   

July 2,

   

June 26,

   

July 2,

   

June 26,

 
   

2017

   

2016

   

2017

   

2016

 

Revenues:

                               

Battery & Energy Products

  $ 16,880     $ 15,759     $ 34,359     $ 32,199  

Communication Systems

    3,059       4,612       7,615       9,005  

Total Revenues

    19,939       20,371     $ 41,974     $ 41,204  
                                 

Cost of Products Sold:

                               

Battery & Energy Products

    12,139       11,095       24,688       22,318  

Communication Systems

    1,579       3,376       4,175       6,581  

Total Cost of Products Sold

    13,718       14,471       28,863       28,899  
                                 

Gross Profit

    6,221       5,900       13,111       12,305  
                                 

Operating Expenses:

                               

Research and Development

    1,185       1,425       2,323       3,081  

Selling, General and Administrative

    3,714       3,976       7,625       8,243  

Total Operating Expenses

    4,899       5,401       9,948       11,324  
                                 

Operating Income

    1,322       499       3,163       981  
                                 

Other Expense

    49       24       142       137  

Income Before Income Taxes

    1,273       475       3,021       844  
                                 

Income Tax Provision

    179       33       266       121  
                                 

Net Income

    1,094       442       2,755       723  
                                 

Net( Income) Loss Attributable to Non-Controlling Interest

    -       4       (6 )     22  
                                 

Net Income Attributable to Ultralife Corporation

  $ 1,094     $ 446     $ 2,749     $ 745  
                                 
                                 

Net Income Per Share Attributable to Ultralife Common Shareholders – Basic

  $ .07     $ .03     $ .18     $ .05  
                                 

Net Income Per Share Attributable to Ultralife Common Shareholders – Diluted

  $ .07     $ .03     $ .17     $ .05  
                                 

Weighted Average Shares Outstanding – Basic

    15,510       15,528       15,461       15,290  
                                 

Weighted Average Shares Outstanding – Diluted

    15,850       15,419       15,752       15,545